The major emphasis of Dr. Sandborg’s work in the past decade has been focused on the future of academic pediatrics and pediatric rheumatology through providing training, research opportunities and environments to nurture and challenge future pediatric rheumatologists and subspecialists, and has now expanded to encompass design of new models of care for children with complex chronic illness.
Following 20+ years at Boston Children’s Hospital, Dr. Fuhlbrigge moved to Denver in 2016 where he is currently Professor of Pediatrics at the University of Colorado - Denver and Section Chief for Pediatric Rheumatology at Children’s Hospital Colorado. He is the current Chair for CARRA and former Vice Chair, Finance Chair and Treasurer. Prior to that he served 2 terms as Chair of the Scleroderma, Vasculitis and Rare Diseases Committee and he continues as an active member of several research workgroups within this committee. In these varied roles, he has been closely involved with the operations of the CARRA research enterprise and a key contributor to strategic initiatives implemented over the past 5 years.
In 2001, as a young faculty member, Dr. von Scheven was invited to attend a small meeting at Stanford to discuss the development of a collaborative research network that would bring research to the patient, and vice versa. What she did not know at the time, was that the newly created network, called the Pediatric Rheumatology Research Network, would eventually become CARRA, and that CARRA would play a central role both in the pediatric rheumatology community and in her own professional life. CARRA has undergone tremendous growth, and has emerged as a respected, productive and well-supported organization with a broad constituent base. We now face new challenges, such as ensuring that our efforts are meaningful and impactful, that we stay focused on the priorities of our diverse community and that we address issues of sustainability.
Dr. Colbert served as the director of the Division of Rheumatology at Cincinnati Children's Hospital Medical Center (CCHMC) of the University of Cincinnati College of Medicine (UCCOM). He is certified in pediatric rheumatology by the American Board of Pediatrics and holds memberships in the American Academy of Pediatrics, the American Association of Immunologists, the American College of Rheumatology, the Society for Pediatric Research, and the American Pediatric Society. His research career has included authoring 53 papers and serving as an investigator on a number of NIAMS and other NIH and industry-funded research studies. Dr. Colbert’s accomplishments have been recognized in numerous honors and awards, including Pfizer Postdoctoral Fellowship and Scholar Awards, the James R. Klinenberg Science Award from the Arthritis Foundation, and the American College of Rheumatology’s Deborah Kredich Pediatric Rheumatology Service Award.
Dr. Kimura is the chief of the Division of Pediatric Rheumatology at the Children’s Hospital at Hackensack University Medical Center, and Professor of Pediatrics at Rutgers New Jersey Medical School. Her research efforts have been directed toward improving the health, treatment and outcomes for patients with JIA and other pediatric rheumatic diseases. She is the current Chair of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), President of CARRA, Inc. and co-Principal Investigator (PI) of the CARRA Registry, which is studying the long-term safety of medications being used to treat JIA. Dr Kimura led the development of the CARRA consensus treatment plans (CTPs) for both systemic JIA and polyarticular JIA, which are now being implemented through CARRA Registry-wide comparative effectiveness studies.
Dr. Harry J. Saal was the founder and CEO of Network General Corporation, the first company wholly dedicated to the area of network diagnostics and the creator of the eponymous "Sniffer" network analyzer. In 2002, Dr. Saal was chosen by the US Department of Justice to lead the Technical Committee charged with monitoring and enforcing the Microsoft Antitrust case. He served as Chairman of the Committee through the May 2011 expiration of the Judgment.
Most recently, he is the Chair of Retrotope, Inc. a pharmaceutical startup, based here in Silicon Valley. Dr. Saal is confident that the compounds under development stand an excellent chance of revolutionizing the treatment and prevention of a wide variety of untreatable neurodegenerative diseases of aging.
Dr. Wallace received her MD from the University of Michigan in 1973. She completed both her residency in pediatrics and fellowship in pediatric rheumatology at the University of Washington. Following this, she was in private practice pediatrics and rheumatology until she joined the University of Washington and Children’s Hospital and Regional Medical Center in 1984. Dr. Wallace’s main focus has been the aggressive treatment of Juvenile Idiopathic Arthritis (JIA) and other Pediatric Rheumatic Diseases. She has published many of the sentinel studies of the use of methotrexate in the treatment of JIA.
Leigh White is an investor and business advisor to start up companies in Silicon Valley. Previously she served as Executive Vice President at CurAgeis Technologies, responsible for building the company’s fatigue management division around new leading edge scientific technology. She joined CurAegis (pronounced like “courageous”) in September 2015 after 6 years as President of Alertness Solutions – a leading fatigue management firm with significant focus on the aviation industry.
Prior to acquiring Alertness Solutions, she spent 14 years as a Silicon Valley venture capital investor. Ms. White holds a Bachelor’s Degree in Finance from Wichita State University. She earned her J.D. from Stanford Law School in 1996 and is a member of the State Bar of California.